Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ticagrelor on Rosuvastatin PK in Healthy Participants
NCT06554821Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Aug 2024; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06554821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554821.